THE IMMUNOTHERAPY OF HEPATOCELLULAR CARCINOMA

Authors

  • Mohammed Alnaggar Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Wei Zhou Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Xue Yang Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Jing qiong Hu Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Feng Liu Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Sheng Rao Deprtment of Oncology ,Tongji Chibi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chibi, Hubei, China.
  • Ke liang Lu Department of Internal Medicine, Maternal and Child Hospital, Ibb, Yemen

DOI:

https://doi.org/10.53555/eijmhs.v6i4.144

Keywords:

Primary liver cancer, Immunotherap, Treatment progress

Abstract

Primary liver cancer is one of the most common malignancies in the world, and surgery-based combined therapy is still being the dominant treatment option. Though surgery is considered to be one of the most effective and curative treatments, many patients have lost their chances of surgical cure as they are in advanced stage of the disease when diagnosed. Thus, the non-surgical treatment in the medical profession has received considerable attention, because 5-year recurrence rate after surgery is also high. In recent years, good progresses have been made in many non-surgical treatments. In this paper, the treatment status of primary liver cancer will be reviewed.

References

. Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB 2012; 14:500-505.

. Sangro B, Gomez-Martin C, de la Mata M, I~narrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59:81-88.

. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955 [PMID: 21145847 DOI: 10.1016/ j.jhep.2010.08.041]

. Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, Li J, Hu Y, Chen Y, Xu K, Wu Y, Yin Z. Allogenic Vγ9Vδ2 T cell as new potential Immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunotherapy Cancer. 2019 Feb 8; 7(1):36. doi: 10.1186/s40425-019-0501-8. PubMed PMID: 30736852; PubMed Central PMCID: PMC6368763.

. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013; 63:11–30.

. Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? Journal of Hepatology. 2012; 56:686–95.

. Alnaggar M, Lin M, Mesmar A, Liang S, Qaid A, Xu K, Chen J, Niu L, Yin Z. Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for

. Stage IV Hepatocellular Carcinoma: Survival Outcome. CellPhysiol Biochem. 2018 Aug 9; 48(5):1882-1893. doi: 10.1159/000492509. [Epub ahead of print] PubMed PMID: 30092590.

. Yang W, Guo C, Liu Q, et al. Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine[J]. Biomedicine & Pharmacotherapy, 2009, 63(6): 404-408.

. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011; 54: 830-834 [PMID: 21145836 DOI: 10.1016/j.jhep.2010.10.013]

. Nakamoto Y, Kaneko S. [Dendritic cell-based immunotherapy for hepatocellular carcinoma] [J]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, 37(3): 413-416. [11] Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP (+) CTLA-4(+) Foxp3 (+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 2013; 73: 2435-2444 [PMID: 23423978 DOI: 10.1158/0008-5472.CAN-12-3381]

. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8 (+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011; 128: 887-896 [PMID: 20473887 DOI: 10.1002/ijc.25397]

. Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ, Yang DL. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011; 17: 3322-3329 [PMID: 21876620 DOI: 10.3748/wjg.v17.i28.3322]

. Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, Kagaya T, Yamashita T, Fushimi K, Kaneko S. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013; 57: 1448-1457 [PMID: 23174905 DOI: 10.1002/ hep.26153]

. Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma [J]. Digestive and Liver Disease, 2009, 41(1): 36-41.

. Tomova R, Antonov K, Ivanova A, et al. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report [J]. Anticancer research, 2009, 29(12): 5241-5244.

. Cheng J. Characterization of human Fas gene. Exon/intron organization and promoter region.J Immunol. 1995; 154 1239–1245.

. Suda T. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.Cell. 1993; 75 1169–1178.

. Curtin JF. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003, 15 983-992.

. Griffith TS. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270 1189-1192.

. Donald B. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377 630-632.

. Higaki K. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol. 1996; 149(2) 429-437.

. Jodo S. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. ClinExpImmunol 1998; 112 166-171. 82 Liver Tumors - Epidemiology, Diagnosis, Prevention and Treatment

. Nagao M. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology. 1999; 30(2) 413-421.

. Agata Y. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. IntImmunol. 1996; 8765–8772.

. Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26) 2443-2454.

. Shi F. PD-1 and PD-L1 upregulation promotes CD8 (+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011; 128(4) 887-896.

. Wu K. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69(20) 8067–8075.

. Chen C. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest. 2008; 26(10) 965-974.

. Shen HW. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.World J Gastroenterol. 2005; 11(38) 5926-5930.

Downloads

Published

2020-12-27

Issue

Vol. 6 No. 4 (2020): EPH - International Journal of Medical and Health Science (ISSN: 2456 - 6063)

Section

Articles

License

Copyright (c) 2020 EPH - International Journal of Medical and Health Science (ISSN: 2456 - 6063)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.